# CLDI (Calidi Biotherapeutics, Inc.) - SEC EDGAR Financial Statements

> Calidi Biotherapeutics, Inc. reported $5.52M in total assets and a net loss of $15.97M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CLDI
- Markdown: https://convexityos.com/fundamentals/CLDI.md
- SEC CIK: 0001855485
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:12 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001855485&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$17.15M | Operating profit |
| Net Income | FY 2025 | -$15.97M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$6.45 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $3.95M | Total debt: $1.02M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | $45K |
| Research & Development | $9.74M | $8.88M | $13.01M | $7.26M |
| Selling, General & Admin | $10.50M | $12.90M | $15.98M | $15.90M |
| Total Operating Expenses | $20.24M | $21.78M | $28.99M | $23.17M |
| **Operating Income** | -$20.24M | -$21.78M | -$28.99M | -$23.13M |
| **EBITDA** | -$18.59M | -$20.24M | -$28.60M | -$22.87M |
| Interest Expense | $100K | $700K | $1.10M | $200K |
| Income Before Tax | -$20.05M | -$22.20M | -$29.20M | -$25.42M |
| Income Tax Expense | $15K | $14K | $16K | $11K |
| **Net Income** | -$19.91M | -$22.14M | -$29.22M | -$25.43M |
| Basic EPS | -$95.20 | -$571.20 | -$277.28 | $478.40 |
| **Diluted EPS** | -$95.20 | -$571.20 | -$277.28 | $478.40 |
| Basic Shares Outstanding | 269 | 42 | 105.4K | 53.2K |
| Diluted Shares Outstanding | 269 | 42 | 105.4K | 53.2K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $2.70M | $2.56M | $2.59M | $2.36M | $2.36M | $2.59M | $2.42M | $1.81M |
| Selling, General & Admin | $1.64M | $1.59M | $1.60M | $2.11M | $2.69M | $3.07M | $2.64M | $2.21M |
| Total Operating Expenses | $4.34M | $4.15M | $4.19M | $4.47M | $5.05M | $5.66M | $5.06M | $4.03M |
| **Operating Income** | -$4.34M | -$4.15M | -$4.19M | -$4.47M | -$5.05M | -$5.66M | -$5.06M | -$4.03M |
| **EBITDA** | -$3.93M | -$3.71M | -$3.76M | -$4.04M | -$4.62M | -$5.26M | -$4.67M | -$3.93M |
| Interest Expense | $23K | $22K | $22K | $0 | $27K | $40K | $100K | $100K |
| Income Before Tax | -$3.64M | -$4.16M | -$4.10M | -$4.06M | -$5.17M | -$5.76M | -$5.06M | -$4.14M |
| Income Tax Expense | $9.0K | $5.0K | $4.0K | -$2.0K | $10K | $4.0K | $3.0K | $3.0K |
| **Net Income** | -$3.65M | -$4.16M | -$4.11M | -$4.06M | -$5.15M | -$5.71M | -$4.99M | -$4.10M |
| Basic EPS | -$1.47 | -$47.04 | -$6.88 | -- | -$35.25 | -$508.00 | -$35.36 | -- |
| **Diluted EPS** | -$1.47 | -$47.04 | -$6.88 | -- | -$35.25 | -$508.00 | -$35.36 | -- |
| Basic Shares Outstanding | 2.5M | 88.5K | 644.2K | -- | 307.0K | 11.2K | 141.1K | -- |
| Diluted Shares Outstanding | 2.5M | 88.5K | 644.2K | -- | 307.0K | 11.2K | 141.1K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $5.60M | $9.60M | $1.95M | $372K | $1.06M |
| **Cash & Short-Term Investments** | $5.60M | $9.60M | $1.95M | $372K | $1.06M |
| Accounts Receivable, Net | -- | -- | -- | $870 | $0 |
| **Total Current Assets** | $6.26M | $10.23M | $4.30M | $786K | $1.48M |
| Property, Plant & Equipment, Net | $781K | $869K | $1.27M | $1.27M | -- |
| Other Non-Current Assets | $19K | $152K | $373K | $725K | -- |
| **Total Non-Current Assets** | $2.60M | $3.96M | $5.72M | $42.45M | $230.3M |
| **Total Assets** | $8.86M | $14.18M | $10.02M | $2.60M | $231.8M |
| Accounts Payable | -- | -- | -- | $51K | $64K |
| Short-Term Debt | $90K | $3.22M | $807K | $5.42M | -- |
| **Total Current Liabilities** | $3.94M | $9.50M | $10.23M | $42.99M | $411K |
| Long-Term Debt | $510K | -- | $1.25M | -- | -- |
| Other Non-Current Liabilities | -- | -- | $1.50M | -- | -- |
| **Total Non-Current Liabilities** | $1.16M | $2.72M | $8.02M | $1.07M | $16.04M |
| **Total Liabilities** | $5.10M | $12.21M | $18.25M | $43.44M | $16.45M |
| **Total Debt (incl. Leases)** | $2.56M | $6.48M | $6.43M | $5.99M | -- |
| Common Stock | $1.0K | $2.0K | $1.0K | $2.0K | -- |
| Retained Earnings | -$141.6M | -$121.7M | -$99.57M | -$70.36M | -$14.69M |
| Accumulated Other Comp. Income | -$13K | -$28K | -$47K | -$14K | -- |
| **Total Stockholders' Equity** | $3.76M | $1.53M | -$8.23M | -$50.44M | -$31.61M |
| Total Equity | $3.76M | $1.97M | -$8.23M | -$50.44M | -$31.61M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.95M | $4.07M | $6.63M | $5.60M | $10.38M | $5.28M | $10.56M | $9.60M |
| **Cash & Short-Term Investments** | $3.95M | $4.07M | $6.63M | $5.60M | $10.38M | $5.28M | $10.56M | $9.60M |
| **Total Current Assets** | $4.74M | $5.43M | $7.35M | $6.26M | $11.03M | $6.05M | $11.49M | $10.23M |
| Property, Plant & Equipment, Net | $704K | $775K | $758K | $781K | $849K | $929K | $795K | $869K |
| Other Non-Current Assets | $0 | $9.0K | $138K | $19K | $140K | $40K | $144K | $152K |
| **Total Non-Current Assets** | $787K | $1.78M | $2.24M | $2.60M | $3.00M | $3.30M | $3.58M | $3.96M |
| **Total Assets** | $5.52M | $7.20M | $9.59M | $8.86M | $14.03M | $9.35M | $15.06M | $14.18M |
| Short-Term Debt | $668K | $45K | $23K | $90K | $472K | $820K | $1.16M | $3.22M |
| **Total Current Liabilities** | $3.73M | $3.24M | $3.84M | $3.94M | $5.19M | $5.35M | $5.43M | $9.50M |
| Long-Term Debt | -- | $555K | $577K | $510K | $128K | -- | -- | -- |
| **Total Non-Current Liabilities** | $166K | $834K | $820K | $1.16M | $1.64M | $1.92M | $2.34M | $2.72M |
| **Total Liabilities** | $3.89M | $4.07M | $4.66M | $5.10M | $6.83M | $7.28M | $7.76M | $12.21M |
| **Total Debt (incl. Leases)** | $1.02M | $1.94M | $2.26M | $2.56M | $2.90M | $3.46M | $4.13M | $6.48M |
| Common Stock | -- | -- | $1.0K | $1.0K | $1.0K | -- | $3.0K | $2.0K |
| Retained Earnings | -$153.5M | -$149.9M | -$145.7M | -$141.6M | -$137.6M | -$132.4M | -$126.7M | -$121.7M |
| Accumulated Other Comp. Income | -$35K | -$26K | -$22K | -$13K | -$13K | -$13K | -$26K | -$28K |
| **Total Stockholders' Equity** | $1.63M | $3.13M | $4.93M | $3.76M | $6.92M | $1.76M | $6.94M | $1.53M |
| Total Equity | $1.63M | $3.13M | $4.93M | $3.76M | $7.20M | $2.08M | $7.30M | $1.97M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$20.06M | -$22.21M | -$29.22M | -$25.43M |
| Depreciation & Amortization | $1.65M | $1.53M | $392K | $260K |
| Stock-Based Compensation | $2.11M | $2.96M | $4.81M | $4.52M |
| Change in Receivables | -- | -- | -- | -$870 |
| Change in Payables | -$1.33M | -$628K | -$6.17M | $1.62M |
| **Operating Cash Flow** | -$21.29M | -$19.69M | -$26.98M | -$13.21M |
| Purchases of Investments | -$50K | -- | -- | -- |
| **Investing Cash Flow** | -$170K | -$16K | -$478K | -$494K |
| **Financing Cash Flow** | $17.46M | $27.36M | $29.04M | $12.09M |
| **Net Change in Cash** | -$3.99M | $7.64M | $1.58M | -$969K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$3.65M | -$4.16M | -$4.11M | -$4.06M | -$5.18M | -$5.76M | -$5.06M | -$4.15M |
| Depreciation & Amortization | $417K | $438K | $426K | $423K | $427K | $407K | $394K | $98K |
| Stock-Based Compensation | $62K | $157K | $231K | $450K | $529K | $522K | $607K | $626K |
| Change in Payables | $411K | $74K | $232K | -$404K | -$191K | $19K | -$752K | -$1.17M |
| **Operating Cash Flow** | -$2.34M | -$4.35M | -$4.12M | -$5.04M | -$4.24M | -$4.88M | -$7.13M | -$5.42M |
| **Investing Cash Flow** | -$23K | -$33K | -$5.0K | -$79K | -$27K | -$57K | -$7.0K | -$5.0K |
| **Financing Cash Flow** | $2.25M | $1.83M | $5.16M | $340K | $9.48M | -$469K | $8.11M | $13.11M |
| **Net Change in Cash** | -$124K | -$2.56M | $1.03M | -$4.78M | $5.21M | -$5.40M | $970K | $7.69M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -51395.6% |
| **Net Profit Margin** | -- | -- | -- | -56504.4% |
| Return on Equity (ROE) | -529.6% | -1443.5% | -- | -- |
| Return on Assets (ROA) | -224.7% | -156.1% | -291.6% | -979.1% |
| Current Ratio | 1.59x | 1.08x | 0.42x | 0.02x |
| Quick Ratio | 1.42x | 1.01x | 0.19x | 0.01x |
| Debt to Equity | 0.68x | 4.22x | -- | -- |
| EPS Growth (YoY) | -- | -- | -158.0% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -979.2% | -557.7% | -385.6% | -529.6% | -288.3% | -1125.4% | -286.8% | -1443.5% |
| Return on Assets (ROA) | -289.2% | -242.5% | -198.4% | -224.7% | -142.2% | -212.3% | -132.1% | -156.1% |
| Current Ratio | 1.27x | 1.68x | 1.92x | 1.59x | 2.12x | 1.13x | 2.12x | 1.08x |
| Quick Ratio | 1.06x | 1.26x | 1.73x | 1.42x | 2.00x | 0.99x | 1.95x | 1.01x |
| Debt to Equity | 0.63x | 0.62x | 0.46x | 0.68x | 0.42x | 1.96x | 0.59x | 4.22x |

## Related Companies

[OZVN (OZ Vision Inc.)](https://convexityos.com/fundamentals/OZVN), [THTG (Tech Tonic Group Corp.)](https://convexityos.com/fundamentals/THTG), [AOXY (Advanced Oxygen Technologies, Inc.)](https://convexityos.com/fundamentals/AOXY), [RDSC (Radiant Strategies Corporation)](https://convexityos.com/fundamentals/RDSC), [ADMG (Adamant DRI Processing and Minerals Group)](https://convexityos.com/fundamentals/ADMG), [VIVC (Vivic Corp.)](https://convexityos.com/fundamentals/VIVC), [ADNH (Advent Technologies Holdings, Inc.)](https://convexityos.com/fundamentals/ADNH), [SKFG (Stark Focus Group, Inc.)](https://convexityos.com/fundamentals/SKFG)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
